News and Community

Drug Administration, Drug Substance, Healthcare Technology, Mfg8, Pli Pass, Wuxi Biologics

July 9, 2026

WuXi Biologics MFG8 Drug Substance Facility Achieves FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy